Related Experiment Video
Updated: Oct 11, 2025
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
15.1K
Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics
Morteza Shams1, Hassan Nourmohammadi1,2, Hamidreza Majidiani1
1Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Biologia
|December 6, 2021
Summary
Researchers designed a novel multimeric vaccine candidate against visceral leishmaniasis (VL). Computational analysis suggests this vaccine can stimulate T cell responses, offering a promising strategy for VL prevention.
Area of Science:
- Parasitology
- Immunology
- Vaccine Development
Background:
- Visceral leishmaniasis (VL) is a severe global disease with no approved human vaccine.
- Current treatment options for VL are limited and pose challenges.
Purpose of the Study:
- To design and computationally evaluate a novel multimeric vaccine candidate against *Leishmania infantum*.
- To assess the immunoinformatic properties and potential efficacy of the designed vaccine.
Main Methods:
- In silico design of a chimeric vaccine incorporating immunodominant epitopes from histone H1, KMP11, LACK, and LeIF antigens.
- Prediction of MHC-I, MHC-II binders, and CTL epitopes, linked by spacers.
- Addition of a TLR-4 agonist and His-tag, followed by structural and immunoinformatic simulations.
Main Results:
- The designed vaccine (184 amino acids, 18.99 kDa) was predicted to be soluble, highly antigenic, and non-allergenic.
- Structural analysis confirmed construct stability and interaction with TLR-4/MD2.
- Immunoinformatics simulations indicated potent T cell stimulation, including increased IFN-γ production.
Conclusions:
- The in silico data supports a highly antigenic vaccine candidate for visceral leishmaniasis.
- The proposed multi-epitope vaccine demonstrates potential for stimulating cellular immune responses for VL prophylaxis.
